Allergy Therapeutics plc (LON:AGY - Get Free Report) shares hit a new 52-week high on Tuesday . The company traded as high as GBX 8.50 ($0.11) and last traded at GBX 8.50 ($0.11), with a volume of 57317 shares changing hands. The stock had previously closed at GBX 8.10 ($0.11).
Allergy Therapeutics Stock Performance
The stock's 50 day moving average is GBX 7.67 and its two-hundred day moving average is GBX 6.94. The stock has a market capitalization of £430.07 million, a price-to-earnings ratio of -8.43, a price-to-earnings-growth ratio of -30.70 and a beta of 1.40. The company has a current ratio of 1.63, a quick ratio of 1.48 and a debt-to-equity ratio of 835.48.
Allergy Therapeutics Company Profile
(
Get Free Report)
Allergy Therapeutics is an international commercial biotechnology company focussed on the treatment and diagnosis of allergic disorders, including aluminium free immunotherapy vaccines that have the potential to cure disease. The Group sells proprietary and third party products from its subsidiaries in nine major European countries and via distribution agreements in an additional ten countries.
Read More
Before you consider Allergy Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Allergy Therapeutics wasn't on the list.
While Allergy Therapeutics currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Just getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
